The acute porphyrias: A diagnostic and therapeutic challenge in internal and emergency medicine

Internal and Emergency Medicine

Volumn 4, Issue 4, 2009, Pages 297-308

  Ventura, Paolo ^a   Cappellini, Maria Domenica ^b   Rocchi, Emilio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute porphyrias; Heme; Heme arginate; Neurovisceral crises; Porphyric acute attack

Indexed keywords

ARGININE; HEME; HEME ARGINATE;

ACUTE INTERMITTENT PORPHYRIA; DIAGNOSTIC ERROR; EMERGENCY MEDICINE; HUMAN; INTERNAL MEDICINE; REVIEW;

ARGININE; DIAGNOSTIC ERRORS; EMERGENCY MEDICINE; HEME; HUMANS; INTERNAL MEDICINE; PORPHYRIA, ACUTE INTERMITTENT;

EID: 70350622441     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-009-0261-4     Document Type: Review

References (50)

1. Kauppinen R (2005) Porphyrias. Lancet 365:241-252.
2. Ventura E, Rocchi E (2001) Le Porfirie. In: Guarini G, Fiorelli G, Malliani A, Violi E, Volpe M (eds) Teodori 2000. Trattato di Medicina Interna.Società Editrice Universo, Roma, pp 2301-2334.
3. Anderson KE, Sassa S, Bishop DF, Desnick RJ (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited diseases. McGraw-Hill, New York, pp 2991-3062.
4. Phillips JD, Bergonia HA, Reilly CA et al (2007) A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 104:5079-5084.
5. Rigal JC, Blanloeil Y (2002) Anaesthesia and porphyria. Minerva Anestesiol 68:326-331.
6. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R (2003) Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39:620-627.
7. Badminton MN, Elder GH (2005) Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 28:277-286.
8. Gouya L, Puy H, Robreau AM et al (2004) Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias. Hum Genet 114:256-262.
9. Kauppinen R (2004) Molecular diagnostics of acute intermittent porphyria. Expert Rev Mol Diagn 4:243-249.
10. Bonkovsky HL, Barnard GF (1998) Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 18:57-65.
11. de Rooij WM, Edixhoven A, Wilson JH (2003) Porphyria: a diagnostic approach. In: Kadish KM, Smith KM, Guillard R (eds) The porphyrin handbook. Elsevier, St Louis, pp 211-245.
12. Grob U, Puy H, Jacob K et al (2006) Biochemical compared to molecular diagnosis in acute intermittent porphyria. J Inherit Metab Dis 29:157-161.
13. Elder GH, Hift RJ, Meissner PN (1997) The acute porphyrias. Lancet 349:1613-1617.
14. Solinas C, Vajda FJ (2008) Neurological complications of porphyria. J Clin Neurosci 15:263-268.
15. Kirsch RE, Meissner PN, Hift RJ (1998) Variegate porphyria. Semin Liver Dis 18:33-41.
16. Martasek P (1998) Hereditary coproporphyria. Semin Liver Dis 18:25-32.
17. Sassa S (1998) ALAD porphyria. Semin Liver Dis 18:95-101.
18. Frith D, Yeung K, Thrush S et al (2005) Lead poisoning-a differential diagnosis for abdominal pain. Lancet 366:2146.
19. Usalan C, Erdem Y, Altun B et al (1996) Severe hyponatremia due to SIADH provoked by acute intermittent porphyria. Clin Nephrol 45:418.
20. Crimlisk HL (1997) The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 62:319-328.
21. Tishler PV, Woodward B, O'Connor J et al (1985) High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry 142:1430-1436.
22. Hultdin J, Schmauch A, Wikberg A et al (2003) Acute intermittent porphyria in childhood: a population-based study. Acta Paediatr 92:562-568.
23. Kauppinen R, von und zu Fraunberg M (2002) Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 48:1891-1900.
24. Kanaan C, Veille JC, Lakin M (1989) Pregnancy and acute intermittent porphyria. Obstet Gynecol Surv 44:244-249.
25. Deybach JC, Badminton M, Puy H et al (2006) European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol Res 55(Suppl 2):S67-S73.
26. Thadani H, Deacon A, Peters T (2000) Diagnosis and management of porphyria. BMJ 320:1647-1651.
27. Andersson C, Lithner F (1994) Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 236:169-175.
28. Andant C, Puy H, Bogard C et al (2000) Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32:933-939.
29. de Verneuil H, Ged C, Boulechfar S, Moreau-Gaudry F (1995) Porphyrias: animal models and prospects for cellular and gene therapy. J Bioenerg Biomembr 27:239-248.
30. Rocchi E, Ventura P, Ronzoni A et al (2004) Pro-oxidant and antioxidant factors in acute intermittent porphyria: family studies. J Inherit Metab Dis 27:251-266.
31. Lindberg RL, Martini R, Baumgartner M et al (1999) Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 103:1127-1134.
32. Seth AK, Badminton MN, Mirza D et al (2007) Liver transplantation for porphyria: who, when, and how? Liver Transpl 13:1219-1227.
33. Shanley BC, Neethling AC, Percy VA, Carstens M (1975) Neurochemical aspects of porphyria: studies on the possible neurotoxicity of delta-aminolaevulinic acid. S Afr Med J 49:576-580.
34. Minder EI (1986) Measurement of 5-aminolaevulinic acid by reversed phase HPLC and fluorescence detection. Clin Chim Acta 161:11-18.
35. Hift RJ, Davidson BP, van der Hooft C et al (2004) Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem 50:915-923.
36. Erlandsen EJ, Jorgensen PE, Markussen S, Brock A (2000) Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements. Scand J Clin Lab Invest 60:627-634.
37. Campbell BC, Brodie MJ, Thompson GG et al (1977) Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. Clin Sci Mol Med 53:335-340.
38. Floderus Y, Sardh E, Moller C et al (2006) Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Clin Chem 52:701-707.
39. Thunell S (2006) (Far) Outside the box: genomic approach to acute porphyria. Physiol Res 55(Suppl 2):S43-S66.
40. Cappellini MD, Martinez di Montemuros F, Di Pierro E, Fiorelli G (2002) Hematologically important mutations: acute intermittent porphyria. Blood Cells Mol Dis 28:5-12.
41. Elder GH, Hift RJ (2001) Treatment of acute porphyria. Hosp Med 62:422-425.
42. Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 71:1-13.
43. Handschin C, Lin J, Rhee J et al (2005) Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122:505-515.
44. Schuurmans MM, Hoffmann F, Lindberg RL, Meyer UA (2001) Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria. Hepatology 33:1217-1222.
45. Krauss GL, Simmons-O'Brien E, Campbell M (1995) Successful treatment of seizures and porphyria with gabapentin. Neurology 45:594-595.
46. Anderson KE, Spitz IM, Sassa S et al (1984) Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med 311:643-645.
47. Cohen SM (2001) Lead poisoning: a summary of treatment and prevention. Pediatr Nurs 27(125/126):129-130.
48. Pimstone NR (2005) Roles and pitfalls of transplantation in human porphyria. Liver Transpl 11:1460-1462.
49. Sardh E, Rejkjaer L, Andersson DE, Harper P (2007) Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet 46:335-349.
50. Yasuda M, Domaradzki ME, Armentano D et al (2007) Acute intermittent porphyria: vector optimization for gene therapy. J Gene Med 9:806-811.